_glp-1-agonists-explained-how-they-work-their-benefits-and-risks-preview-1.jpg "GLP-1 Agonists, Explained: How They Work, Their Benefits and Risks from glp 1 agonists drugs Video Screenshot Preview 1")
Gallery_glp-1-agonists-explained-how-they-work-their-benefits-and-risks-preview-3.jpg "GLP-1 Agonists, Explained: How They Work, Their Benefits and Risks from glp 1 agonists drugs Video Screenshot Preview 3")
Gallery_glp-1-agonists-explained-how-they-work-their-benefits-and-risks-preview-hqdefault.jpg "GLP-1 Agonists, Explained: How They Work, Their Benefits and Risks from glp 1 agonists drugs Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 3 minutes 25 seconds
👁 View: 8.9K times
Play Audio:👁 View: 8.9K times
Description:
CardioVisual
CardioVisual
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_glucagon-like-peptide-glp-1-and-the-treatment-of-diabetes.webp "Medicosis Perfectionalis")
_5-month-weight-loss-results-124124-compounded-semaglutide-semaglutide-weightloss-glp1.webp "Risa Beesa")
⏲ 8 minutes 20 seconds 👁 7.9K
_new-hope-for-patients-with-treatment-resistant-depression.webp "1 in 5 people could be diagnosed with depression or another serious mental illness in their lives. For some, a drug which can cause a loss of feeling or awareness is showing promising signs against treatment-resistant depression. If this story has raised issues for you, you can call Lifeline on 13 11 14")
_dr-jason-fungs-brutally-honest-opinion-on-ozempic.webp "The Diary Of A CEO Clips")
_gary-taubes-unintended-consequences-of-weight-loss-wonder-drugs.webp "Did you know that doctors were treating diabetic patients with high-fat low-carb diets all the way back in the 1700s? nnThough high-fat ketogenic diets were found to effectively treat diabetes for over a century, they were largely abandoned due to the rapid adoption of insulin in the 1920s, which was considered then to be a miracle cure. nnPrioritizing drugs over lifestyle with insulin therapy, however, led to unexpected long term complications in patients, including damage to large and small bl")
_ep-118-my-glp-1-experience-124-quick-amp-dirty.webp "Dr. Tyna Moore")
_new-glp-1-weight-loss-supplement-better-than-semaglutide-124-dr-stirrett.webp "Dr. Stirrett")
⏲ 8 minutes 50 seconds 👁 2.8K
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.webp "New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand")
_glucagon-like-peptide-glp-1-and-the-treatment-of-diabetes.jpg)
_5-month-weight-loss-results-124124-compounded-semaglutide-semaglutide-weightloss-glp1.jpg)
_new-hope-for-patients-with-treatment-resistant-depression.jpg)
_dr-jason-fungs-brutally-honest-opinion-on-ozempic.jpg)
_gary-taubes-unintended-consequences-of-weight-loss-wonder-drugs.jpg)
_ep-118-my-glp-1-experience-124-quick-amp-dirty.jpg)
_new-glp-1-weight-loss-supplement-better-than-semaglutide-124-dr-stirrett.jpg)
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.jpg)
![[+]](/images/menu.gif){kind=small}